Korea Investment CORP Boosts AbbVie Stake by 13.9%

The fund now owns over 1.5 million shares of the pharmaceutical company.

Published on Mar. 8, 2026

Korea Investment CORP, a major institutional investor, increased its holdings in AbbVie Inc. (NYSE:ABBV) by 13.9% in the third quarter, according to a recent SEC filing. The fund now owns 1,550,150 shares of the pharmaceutical company's stock, making it one of AbbVie's largest shareholders.

Why it matters

AbbVie is a leading global biopharmaceutical company with a diverse portfolio of specialty medicines. Institutional investors like Korea Investment CORP closely monitor and adjust their positions in major pharmaceutical stocks like AbbVie, which can signal broader market trends and investor sentiment around the company's performance and future prospects.

The details

In its 13F filing, Korea Investment CORP reported that it added 188,587 shares of AbbVie during the third quarter, bringing its total stake to over 1.5 million shares. This represents approximately 0.09% of AbbVie's outstanding shares. The fund's increased investment in AbbVie is likely driven by the company's strong financial results, pipeline of new therapies, and growth potential.

  • Korea Investment CORP filed its 13F report for the third quarter of 2026 on March 8, 2026.

The players

Korea Investment CORP

A major South Korean sovereign wealth fund that manages over $200 billion in assets globally.

AbbVie Inc.

A global biopharmaceutical company that develops and commercializes innovative therapies for complex and chronic medical conditions.

Got photos? Submit your photos here. ›

The takeaway

Korea Investment CORP's increased stake in AbbVie reflects the fund's confidence in the pharmaceutical company's long-term growth potential. As a major institutional investor, Korea Investment CORP's portfolio moves can provide valuable insights into broader market trends and investor sentiment around leading healthcare stocks.